Outcomes from the International Society of Nephrology Haemolytic Uraemic Syndromes International Forum.

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 15 06 2024
revised: 07 08 2024
accepted: 04 09 2024
medline: 13 10 2024
pubmed: 13 10 2024
entrez: 12 10 2024
Statut: aheadofprint

Résumé

The haemolytic uraemic syndromes (HUS) are a heterogeneous group of conditions only some of which are mediated by complement (CaHUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included: the nomenclature of HUS; novel complement testing strategies; identification of biomarkers; genetic predisposition to aHUS; optimal dosing and withdrawal strategies for C5 inhibitors; treatment of kidney transplantation recipients; disparity of access to treatment; and the next generation of complement inhibitors in CaHUS. The current rationale for optimal patient management is described.

Identifiants

DOI: 10.1016/j.kint.2024.09.012 PMID: 39395628
pubmed: 39395628
pii: S0085-2538(24)00705-1
doi: 10.1016/j.kint.2024.09.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

D Kavanagh (D)

National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address: david.kavanagh@ncl.ac.uk.

G Ardissino (G)

Center for HUS Prevention, Control and Management Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

V Brocklebank (V)

National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

R N Bouwmeester (RN)

Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, Netherlands.

A Bagga (A)

Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

R Ter Heine (R)

Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.

S Johnson (S)

National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Great North Children's Hospital, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle, United Kingdom.

C Licht (C)

Division of Nephrology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

A L T Ma (ALT)

Paediatric Nephrology Centre, Hong Kong Children's Hospital, Hong Kong, China; Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China.

M Noris (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Italy.

M Praga (M)

Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain; Medicine Department, Universidad Complutense de Madrid, Madrid, Spain.

E Rondeau (E)

Intensive Care Nephrology and Transplantation Department, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (AP-HP) and Sorbonne Université, Paris, France.

A Sinha (A)

Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

R J H Smith (RJH)

Molecular Otolaryngology and Renal Research Laboratories, The University of Iowa, Iowa City, IA, USA.

N S Sheerin (NS)

National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

H Trimarchi (H)

Nephrology Service, Hospital Britanico de Buenos Aires, Buenos Aires C1280 AEB, Argentina.

J F M Wetzels (JFM)

Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Nephrology, Nijmegen, Netherlands.

M Vivarelli (M)

Division of Nephrology, Laboratory of Nephrology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.

N C A J Van de Kar (NCAJ)

Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, Netherlands.

L A Greenbaum (LA)

Division of Pediatric Nephrology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Electronic address: lgreen6@emory.edu.

Classifications MeSH